Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics
J. Clin. Invest. Leo Kager, et al. 115:110 doi:10.1172/JCI22477 [
Go to this article.]
Figure 3Gene expression of
FPGS and 3 transporters with known MTX transport capacity in ALL subtypes. Box plots with medians, quartiles, and ranges excluding outliers (circles) of log mRNA expression are depicted for folylpolyglutamate synthetase (
FPGS) (
A), reduced folate carrier (
RFC, or
SLC19A1) (
B), multidrug resistance–associated protein 1 (
MRP1, or
ABCC1) (
C), and breast cancer resistance protein (
BCRP, or
ABCG2) (
D). Data from 197 patients were plotted (BHD,
n = 42; BNHD,
n = 58;
E2A-PBX1,
n = 21; T-ALL,
n = 35;
TEL-AML1,
n = 41).
P values were determined by the Kruskal-Wallis test. The red boxes indicate subtypes in which gene expression was significantly higher, whereas the green boxes indicate subtypes with significantly lower expression of the gene depicted.
